Patents by Inventor Martin DEVENPORT

Martin DEVENPORT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF HIF-1-ALPHA INHIBITORS IN CANCER IMMUNOTHERAPY
    Publication number: 20240139280
    Abstract: The present invention relates to the use of hypoxia-inducible factor (HIF) inhibitors in cancer immunotherapy. Specifically, the disclosure provides methods of treating a cancer in a subject in need of cancer immunotherapy, comprising administering a HIF-1a inhibitor to the subject and a second cancer immunotherapeutic agent to the subject, wherein the HIF-1a inhibitor comprising echinomycin, and wherein the second cancer immunotherapeutic agent comprising an anti-CTLA-4 antibody including Ipilimumab or Tremelimumab.
    Type: Application
    Filed: April 13, 2022
    Publication date: May 2, 2024
    Inventors: Yin Wang, Yang Liu, Pan Zheng, Martin Devenport, Yan Liu, Christopher Bailey
  • Methods of use of CD24 for the prevention and treatment of leukemia relapse
    Patent number: 11911441
    Abstract: The present invention relates to the use of a CD24 protein for preventing or treating relapse of a cancer in a subject. The present invention also relates to the use of a CD24 protein for reducing cancer stem cell activity.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: February 27, 2024
    Assignees: ONCOIMMUNE, INC., UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Yang Liu, Pan Zheng, Martin Devenport
  • Chimeric and Humanized Anti-Human CTLA4 Monoclonal Antibodies and Uses Thereof
    Publication number: 20230391870
    Abstract: This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.
    Type: Application
    Filed: March 22, 2023
    Publication date: December 7, 2023
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT
  • Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
    Patent number: 11629188
    Abstract: This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: April 18, 2023
    Assignee: ONCOC4, INC.
    Inventors: Yang Liu, Pan Zheng, Martin Devenport
  • METHODS OF USE OF SOLUBLE CD24 FOR TREATING SARS-COV-2 INFECTION
    Publication number: 20230103352
    Abstract: Provided is the use of a CD24 protein for treating a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
    Type: Application
    Filed: February 10, 2021
    Publication date: April 6, 2023
    Applicant: Oncoimmune, Inc.
    Inventors: Xianfeng Fang, Yang Liu, Pan Zheng, Martin Devenport, Dongling Li, Libing Mu
  • METHODS OF USE OF SOLUBLE CD24 FOR TREATING VIRAL PNEUMONIA
    Publication number: 20230108492
    Abstract: Provided is the use of a CD24 protein for treating viral pneumonia.
    Type: Application
    Filed: February 10, 2021
    Publication date: April 6, 2023
    Inventors: Yang Liu, Pan Zheng, Martin Devenport, Renrong Tian, Yongtang Zheng
  • Methods of use of soluble CD24 for treating lupus nephritis
    Patent number: 11571461
    Abstract: The present invention relates to the use of a CD24 protein for treating Systemic Lupus Erythematosus (Lupus, SLE).
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: February 7, 2023
    Assignee: ONCOIMMUNE, INC.
    Inventors: Yang Liu, Pan Zheng, Martin Devenport
  • Methods of use of soluble CD24 for treating immune related adverse events in cancer therapies
    Patent number: 11547741
    Abstract: The present invention relates to a CD24 protein for treating immune-related adverse events (irAEs) associated with cancer immunotherapy. Provided herein is a method of treating, mitigating, minimizing, or preventing immunerelated adverse events (irAEs) associated with a cancer immunotherapy by administering a CD24 protein to a subject in need thereof. The irAE may be diarrhea or another gastrointestinal disorder, pure red cell aplasia, microcytic anemia, lupus, autoimmune nephritism, autoimmune hepatitis, pneumonitis, myocarditis, pericarditis, endocrinopathy, Addison's disease, hypogonadism, Sjogren's syndrome, or type I diabetes. The CCD24 protein may comprise a mature human CD24 or a variant thereof.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: January 10, 2023
    Assignees: OncoImmune, Inc., Children's National Medical Center
    Inventors: Yang Liu, Pan Zheng, Martin Devenport, Mingyue Liu
  • CD80 and CD86 Binding Protein Compositions and Uses Thereof
    Publication number: 20220259285
    Abstract: This invention relates to CTLA-4 protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy.
    Type: Application
    Filed: February 22, 2022
    Publication date: August 18, 2022
    Applicants: ONCOC4, INC., CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT, Wei WU, Xuexiang DU, Mingyue LIU, Fei TANG
  • CD80 and CD86 Binding Protein Compositions and Uses Thereof
    Publication number: 20220259286
    Abstract: This invention relates to CTLA-4 protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy.
    Type: Application
    Filed: February 22, 2022
    Publication date: August 18, 2022
    Applicants: ONCOC4, INC., CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT, Wei WU, Xuexiang DU, Mingyue LIU, Fei TANG
  • METHODS OF USE OF SOLUBLE CD24 FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS
    Publication number: 20220125874
    Abstract: The present invention relates to the use of a CD24 protein for treating Systemic Lupus Erythematosus (Lupus, SLE).
    Type: Application
    Filed: March 6, 2018
    Publication date: April 28, 2022
    Applicant: ONCOIMMUNE, INC.
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT
  • Methods of Use of Soluble CD24 for Neuroprotection and Remyelination
    Publication number: 20220098278
    Abstract: The present invention relates to compositions and their use in methods of protecting and maintaining oligodendrocytes, and of treating demyelinating disorders
    Type: Application
    Filed: September 30, 2021
    Publication date: March 31, 2022
    Applicants: Oncolmmune, Inc., Children's National Medical Center
    Inventors: Yang Liu, Pan Zheng, Martin Devenport, Ning Li
  • CD80 and CD86 binding protein compositions and uses thereof
    Patent number: 11261233
    Abstract: This invention relates to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy. Specifically, the disclosure provides a CTLA-4 protein comprising a mutant extracellular domain of CTLA-4, wherein the CTLA-4 protein exhibits reduced binding to an anti-CTLA-4 antibody as compared to a wild-type extracellular domain of CTLA-4, wherein the anti-CTLA-4 antibody has anti-cancer immunotherapeutic activity.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: March 1, 2022
    Assignees: ONCOC4, INC., CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Yang Liu, Pan Zheng, Martin Devenport, Wei Wu, Xuexiang Du, Mingyue Liu, Fei Tang
  • Targeting CD24-Siglec Interactions for Treating Subjects with Prediabetes or Diabetes
    Publication number: 20220000974
    Abstract: Provided herein are methods and compositions for lowering low-density lipoprotein cholesterol or glucose levels, and for treating subjects with prediabetes or diabetes by targeting CD24-Siglec interactions.
    Type: Application
    Filed: February 5, 2020
    Publication date: January 6, 2022
    Inventors: Yang Liu, Pan Zheng, Xu Wang, Martin Devenport
  • Targeting CD24-Siglec Interactions for the Treatment and Prevention of Nonalcoholic Steatohepatitis
    Publication number: 20220000973
    Abstract: Provided herein are methods and compositions for the prevention and treatment of nonalcoholic steatohepatitis (NASH) by targeting the CD24-Siglec axis.
    Type: Application
    Filed: February 5, 2020
    Publication date: January 6, 2022
    Inventors: Yang Liu, Pan Zheng, Xu Wang, Mingyue Liu, Martin Devenport
  • METHODS OF USE OF CD24 FOR THE PREVENTION AND TREATMENT OF LEUKEMIA RELAPSE
    Publication number: 20210268061
    Abstract: The present invention relates to the use of a CD24 protein for preventing or treating relapse of a cancer in a subject. The present invention also relates to the use of a CD24 protein for reducing cancer stem cell activity.
    Type: Application
    Filed: June 3, 2019
    Publication date: September 2, 2021
    Applicants: ONCOIMMUNE, INC, UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Yang Liu, Pan Zheng, Martin Devenport
  • METHODS OF USE OF CD24 FOR THE PREVENTION AND TREATMENT OF GRAFT VERSUS HOST DISEASE AND MUCOSITIS
    Publication number: 20210228680
    Abstract: The present invention relates to the use of a CD24 protein for preventing or treating Graft versus Host Disease and mucositis.
    Type: Application
    Filed: June 3, 2019
    Publication date: July 29, 2021
    Applicant: ONCOIMMUNE, INC
    Inventors: Yang Liu, Pan Zheng, Martin Devenport
  • ANTI-CD24 COMPOSITIONS AND USES THEREOF
    Publication number: 20210214458
    Abstract: Provided herein are anti-CD24 antibodies that selectively bind human CD24 expressed in cancer cells, but not human CD24 expressed in non-cancerous cells, and the use of such antibodies in cancer therapy.
    Type: Application
    Filed: May 13, 2019
    Publication date: July 15, 2021
    Applicants: ONCOIMMUNE, INC, CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Yang Liu, Pan Zheng, Rhonda Flores, Hung-Yen Chou, Zhihong Xue, Peiying Ye, Martin Devenport
  • Use of CD24 Proteins for Treating Leptin-Deficient Conditions
    Publication number: 20210162006
    Abstract: This invention relates to the use of a CD24 protein for treating leptin-deficient conditions, such as lipodystrophy, by increasing the level of circulating leptin.
    Type: Application
    Filed: October 12, 2020
    Publication date: June 3, 2021
    Applicant: ONCOIMMUNE, INC.
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT
  • METHODS OF SELECTING AND DESIGNING SAFER AND MORE EFFECTIVE ANTI-CTLA-4 ANTIBODIES FOR CANCER THERAPY
    Publication number: 20210047410
    Abstract: The present invention relates to compositions of anti-CTLA-4 antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for the reduction of autoimmune side effects compared to other immunotherapeutic agents.
    Type: Application
    Filed: January 29, 2019
    Publication date: February 18, 2021
    Applicants: Oncolmmune, Inc., Children's Research Institute, Children's National Medical Center
    Inventors: Yang Liu, Pan Zheng, Fei Tang, Mingyue Liu, Martin Devenport, Xuexiang Du, Yan Zhang